Why the study?
Do calcineurin inhibitors (cyclosporin and FK506) prevent cardiac hypertrophy in rodent models of hypertrophic cardiomyopathy and pressure-overload hypertrophy?
Do calcineurin inhibitors (cyclosporin and FK506) prevent cardiac hypertrophy in rodent models of hypertrophic cardiomyopathy and pressure-overload hypertrophy?
Calcineurin inhibition prevents cardiac hypertrophy in rodent models, identifying a critical pathogenic pathway and suggesting a potential therapeutic strategy for human hypertrophic cardiomyopathy.
Prevents hypertrophy in rodent models; leaves open whether calcineurin inhibition translates to safe human HCM therapy.
Hypertrophic cardiomyopathy (HCM) is an inherited form of heart disease that affects 1 in 500 individuals. Here it is shown that calcineurin, a calcium-regulated phosphatase, plays a critical role in the pathogenesis of HCM. Administration of the calcineurin inhibitors cyclosporin and FK506 prevented disease in mice that were genetically predisposed to develop HCM as a result of aberrant expression of tropomodulin, myosin light chain-2, or fetal beta-tropomyosin in the heart. Cyclosporin had a similar effect in a rat model of pressure-overload hypertrophy. These results suggest that calcineurin inhibitors merit investigation as potential therapeutics for certain forms of human heart disease.
No takes yet. Share an insight, caveat, or question.
Sussman et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: